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Background: The T790M mutation of epithelial growth factor receptor (EGFR) is a major cause of the acquired
resistance to EGFR tyrosine kinase inhibitor (EGFR-TKIs) treatment for lung cancer patients. The Hippo pathway
effector, TAZ, has emerged as a key player in organ growth and tumorigenesis, including lung cancer.
Results: In this study, we have discovered high TAZ expression in non-small cell lung cancer (NSCLC) cells
harboring dual mutation and TAZ depletion sensitized their response to EGFR-TKIs. Mechanistically, knockdown of
TAZ in T790M-induced resistant cells leaded to reduced anchorage-independent growth in vitro, tumor formation
and resistance to gefitinib in vivo, correlated with epithelial-mesenchymal transition (EMT) and suppressed migration
and invasion. Furthermore, we confirmed CTGF and AXL, novel EMT markers and potential therapeutic targets for
overcoming EGFR inhibitor resistance, as directly transcriptional targets of TAZ.
Conclusions: Taken together, this study suggests that expression of TAZ is an intrinsic mechanism of T790M-induced
resistance in response to EGFR-TKIs. Combinational targeting on both EGFR and TAZ may enhance the efficacy of
EGFR-TKIs in acquired resistance of NSCLC.
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Non-small cell lung cancer (NSCLC) is the leading cause
of cancer-related deaths worldwide. Despite the benefits
shown with epidermal growth factor receptor tyrosine kin-
ase inhibitor (EGFR-TKI) treatment in patients with TKI-
sensitive EGFR mutations such as delE746-A750 (exon
19) and L858R (exon 21), most patients ultimately relapse
due to the development of drug resistance. A secondary
point mutation in exon 20 of EGFR, which leads to subs-
titution of methionine for threonine at position 790
(T790M), accounted for more than half of the cases with
NSCLC who developed acquired resistance to the first-
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unless otherwise stated.second-generation EGFR-TKIs, which form covalent, irre-
versible bonds with the target, are thought to be one strat-
egy to overcome resistance. However, mounting studies
have shown their limited activity in cells with T790M mu-
tations [2] given acquiring ligand-independent oncogenic
potential [3], more aggressive tumor phenotype and affect-
ing other pathways [4]. Therefore, to develop an effective
therapy for patients harboring EGFR T790M is important
to overcome the acquired resistance.
The transcriptional co-activator with PDZ-binding motif
(TAZ), also known as WWTR1 for WW domain contain-
ing transcription regulator 1, was originally identified as a
14-3-3-binding proteins. Both TAZ and its paralog, Yes-
associated protein (YAP), are key effectors of the Hippo
pathway. Unlike YAP, knock-out of TAZ gene in mice does
not overtly affect mouse development or fertility but se-
lectively affects the construction and function of the lung
and kidney [5]. TAZ is known to bind to a variety of tran-
scription factors to modulate mesenchymal stem cellis an Open Access article distributed under the terms of the Creative Commons
rg/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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crosstalk with other signaling pathways [8] and mechano-
transduction [9].
Recent studies showed that TAZ promoted lung cancer/
epithelial cell proliferation in vitro and tumor develop-
ment in vivo [10]. Higher TAZ expression was associated
with poor differentiation, shorter survival and metastasis
in lung cancer patients [11]. Lately, microarray screening
demonstrated that EGFR ligands (amphiregulin, epiregulin
and neuregulin 1) were downstream targets of TAZ and
EGFR signaling pathway was activated in NSCLC tissues
with high TAZ expression [12,13]. However, the roles of
TAZ in therapeutic response of EGFR-TKI have not been
explored. In this study, we provide evidence that TAZ-
mediated tumorigenesis and progression correlated with
gefitinib sensitivity in lung adenocarcinoma cells harbor-
ing EGFR T790M mutation.
Results
High TAZ expression in NSCLC cells harboring EGFR
T790M mutation
To explore the expression of TAZ in gefitinib-sensitive and
resistant NSCLC, we first examined the endogenousFigure 1 Enhanced expression of TAZ in gefitinib-resistant cell. (A) Ly
adenocarcinoma cell lines A549, cisplatin-resistant A549/DDP, gefitinib-sens
using anti-TAZ antibodies. The levels of GAPDH were detected as loading c
examined by real-time PCR. The endogenous b-actin RNA was used as the
analyzed by western blot. The levels of histone H3 were detected as loadin
graph beside. Data are shown as means ± SEM. n=3. Statistical analyses we
microscopy of immunofluorescent staining of TAZ in PC9 and PC9/GR cells
was used to stain nuclei.expression of TAZ by western blot (Figure 1A) and real-
time PCR (Figure 1B) using several lung cell lines, includ-
ing human bronchial epithelial cell line 16HBE, lung
adenocarcinoma cell lines A549, cisplatin-resistant A549/
DDP, gefitinib-sensitive PC9 (EGFR delE746-A750) and
gefitinib-resistant PC9/GR derived from PC9 harboring
T790M mutation (Additional file 1: Table S1). We found
that TAZ expressed in all NSCLC cell lines, especially rela-
tive level of TAZ mRNA in PC9/GR was 2.84-fold higher
than that in PC9 cells. The functional role of TAZ is differ-
ent according to cellular localization. We subsequently
compared the nuclear accumulation of TAZ between PC9
and PC9/GR by immunoblot analysis using nuclear frac-
tions (Figure 1C). Gray value analysis suggested TAZ nu-
clear protein level in PC9/GR was 1.50-fold higher than
that in PC9. Confocal microscopy also showed that the
majority of the TAZ protein in PC9/GR is localized in the
nucleus using immunofluorescence staining (Figure 1D).
Effect of TAZ on sensitivity of NSCLC cells to gefitinib
To confirm that TAZ was responsible for gefitinib sensitiv-
ity in lung cancer cells, we first overexpressed TAZ in PC9
cells and knocked down TAZ in TAZ-high/drug-resistantsates derived from human bronchial epithelial cell line 16HBE, lung
itive PC9 and gefitinib-resistant PC9/GR were analyzed by western blot
ontrols. (B) Relative mRNAs of TAZ in lung cancer cell lines were
internal control. (C) Nuclear fractions in PC9 and PC9/GR cell lines were
g controls. Densitometric evaluation of TAZ:H3 ratios is illustrated in
re carried out using Student’s t-test. Significance: * P<0.05. (D) Confocal
. Scale bar = 100 mm for original picture and 25 mm for inset. Dapi
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munoblot for pAkt, tAkt, pERK and tERK, downstream
intracellular signaling pathways of EGFR, showed that
pAkt level correlated with expression of TAZ (Figure 2A
and D). Compared with control (PC9 pEX2), overexpres-
sion of TAZ in PC9 (PC9 pEX2-TAZ) reduced sensitivity
to growth inhibition induced by gefitinib (Figure 2B). The
half maximal inhibitory concentration (IC50) values of
PC9 cells to gefitinb in control and pEX2-TAZ group were
0.32 ± 0.01 μmol/L and 0.57 ± 0.01 μmol/L, respectively.
LY294002, as a inhibition of Akt signaling, abolished
descreased sensitivity to gefitinib of TAZ-driven in PC9
cell (Figure 2C). Knockdown of TAZ by both shTAZ1 and
shTAZ2 in PC9/GR cells sensitized their response to gefi-
tinib (Figure 2E). The IC50 values of PC9/GR cells to gefi-
tinib in negative control (shNC), shTAZ1 and shTAZ2
group were 29.18 ± 0.08 μmol/L, 18.26 ± 0.09 μmol/L and
12.19 ± 0.18 μmol/L, respectively. Meanwhile, knockdown
of TAZ in H1975 cells harboring EGFR-T790M also sensi-
tized their response to gefitinib (Figure 2F).Figure 2 Effect of TAZ on the sensitivity of NSCLC cells to gefitinib. (A
subjected to western blot by using anti-TAZ, anti-pAkt, anti-tAkt, anti-pERK
descreased gefitinib sensitivity in PC9 cells. Cells were transfected and then
was accessed by MTT assay as described in Methods. The inhibition rate w
ratio (%) = [1- A490 (experimental group)/A490 (Control group)] × 100. (C)
descreased sensitivity to gefitinib of PC9 cell. (D) shRNAs against different r
cells. Expressions of TAZ, pAkt, tAkt, pERK and tERK were detected by weste
knockdown. (F) Enhanced sensitivity to gefitinib after TAZ knockdown wer
are described as in (B). Results are expressed as means ± SEM from three i
using Student’s t-test.TAZ is important for tumorigenesis and resistant to
gefitinib of PC9/GR
To examine the importance of TAZ in the tumorigenesis
of PC9/GR cells, we generated stable cells (PC9/GR-shNC,
PC9/GR-shTAZ1 and PC9/GR-shTAZ2) by G418 selec-
tion. We assessed the anchorage-independent growth cap-
ability of PC9/GR-shTAZ cells. PC9/GR-shNC cells grew
well in soft agar, whereas colony-forming rates were
reduced dramatically for PC9/GR-shTAZ1 and PC9/
GR-shTAZ2 compared with control group (P<0.01 and
P<0.001, respectively) (Figure 3A). We subsequently ex-
amined whether TAZ contributes to tumor formation in
nude mice. PC9/GR-shTAZ2 cells and PC9/GR-shNC cells
were separately injected into the thigh of nude mice and
the growth of the tumors was monitored. Compared
with PC9/GR-shNC group (right thigh), PC9/GR-shTAZ2
group (left thigh) were compromised in forming tumors at
29th days following the injection (tumor volume: 301.31 ±
46.00 mm3 versus 78.13 ± 20.23 mm3, Figure 3B). The
mean tumor growth curve of the resulting tumors was) Protein lysate extracted from PC9 cells expressing pEX2-TAZ were
and anti-tERK antibodies, respectively. (B) Overexpression of TAZ
exposed to various doses of gefitinib for 48 h and viability
as calculated according to the following formula: inhibition
LY294002, as a inhibition of Akt signaling, abolished TAZ-driven
egions of TAZ mRNA (shTAZ1 and shTAZ2) were expressed in PC9/GR
rn blot. (E) enhanced sensitivity of PC9/GR cells to gefitinib after TAZ
e detected in H1975 cells. Procedures and conditions for inhibition rate
ndependent experiments (*P<0.05). Statistical analyses were carried out
Figure 3 TAZ knockdown in PC9/GR cells suppresses anchorage-independent growth, tumorigenesis and resistant to gefitinib in vivo.
(A) Two hundred stable GR-shNC, GR-shTAZ1 and GR-shTAZ2 cells were plated onto 6-well plates and a colony formation assay was assessed and
photographed. The rate of colony formation was calculated as follows: colony-forming rate = (average colony number/ plated single cell number) ×
100%. The colony-forming rates of GR-shTAZ cells were reduced drastically compared with control group. Results are expressed as means ± SEM from
three independent experiments (**P<0.01, ***P<0.001). (B) PC9/GR cells with stable expression of shTAZ2 and shNC were inoculated subcutaneously
into right and left flanks of nude mice (n = 6 per group), respectively. Representative photographs of nude mice 29 days after inoculation are shown.
(C) Tumor growth curve is indicated. (D) Mice bearing PC9/GR xenografts were treated daily with gefitinib at indicated doses. Data represent
means ± SEM (*P<0.05, **P<0.01). Statistical analyses were carried out using Student’s t-test.
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statistically significant difference in terms of survival. To
test the resistant changes in vivo, mice bearing established
PC9/GR-shNC and PC9/GR-shTAZ2 tumor xenografts
were treated orally with gefitinib. Response to treat-
ment was assessed by tumor growth inhibition. These
results support the suggestion that down-regulation of
TAZ sensitize gefitinib in vivo (Figure 3D).
TAZ mediates epithelial-mesenchymal transition (EMT) of
gefitinib-resistant PC9/GR
Since expression of TAZ promoted EMT in breast cancer
cells and was responsible for their resistance to Taxol, we
analyzed these changes induced by TAZ knockdown in
PC9/GR cells. We observed morphologic differences be-
tween the control and TAZ knockdown cells using a light
microscope. The spindle form of the PC9/GR-shNC cells
changed to a round shape and TAZ knockdown in PC9/GR
cells resulted in clusters of more densely compact sheets of
cells, suggesting that epithelioid-like morphological changes
might have occurred (Figure 4A). We subsequently ana-
lyzed the expression of epithelial and mesenchymal markerproteins using western blot. Compared with the PC9/
GR-shNC cells, E-cadherin expression was drastically
increased and vimentin expression was reduced in TAZ
knockdown cells. In addition, two factors, connective
tissue growth factor (CTGF) and anexelekto (AXL),
which were considered to be the target genes of TAZ
and induce EMT, were decreased by western blot
(Figure 4B) and real-time PCR. We also detected these
proteins in PC9 cells with overexpression of TAZ
(Figure 4B). To further demonstrate transcriptional ac-
tivity of TAZ on CTGF and AXL expression, we con-
ducted luciferase reporter assays in 16HBE (Figure 4C).
The pGL3-basic Luc vector subcloned with the CTGF/
AXL promoter and the pEX2-TAZ or pEX2-TAZ-S51A
plasmids were co-transfected into each cell line, and
after 48 h we measured the luciferase activities. The lu-
ciferase activities of the CTGF/AXL promoter were sig-
nificantly enhanced in 16HBE when co-transfected with
the TAZ gene, but not with the vector control and
pEX2-TAZ-S51A, which disrupts the TEAD transcrip-
tion factors binding (P < 0.001, respectively). The re-
sults also were confirmed in PC9/GR cells (Figure 4D).
Figure 4 TAZ mediates EMT of gefitinib-resistant PC9/GR. (A) TAZ knockdown in PC9/GR cells resulted in a morphology change in PC9/GR
by a light microscope. The spindle form of the PC9/GR-shNC cells changed to a round shape. The cell density of the clusters was obviously
enhanced in the PC9/GR-shTAZ cells. (B) Cell lysates from PC9/GR and PC9 cells expressing vector, shTAZ and PEX2-TAZ were separated and
probed with antibodies for epithelial marker and mesenchymal markers as indicated. TAZ knockdown in PC9/GR cells increased E-cadherin and
decreased vimentin, CTGF and AXL. All data were normalized to GAPDH. (C) Luciferase reporter assay in 16HBE cells with TAZ or TAZ-S51A
overexpression. 16HBE cells co-transfected with pGL3-CTGF/pGL3-AXL and pEX2-TAZ showed significantly elevated reporter activity compared
with controls. Meanwhile, cells co-transfected with pEX2-TAZ-S51A, which disrupts the TEAD binding, exhibited decreased luciferase activity
compared with pEX2-TAZ. Cells were harvested 48 h after transfection for measurement of luciferase activity in all experiments. (D) Luciferase
reporter assay in PC9/GR cells. Total amounts of DNA and RNA were kept constant. Results are expressed as means ± SEM from three
independent experiments. Statistical analyses were carried out using Student’s t-test.
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and invasion
Next, we examined migratory and invasive potential, which
are considered functional hallmarks of EMT. We compared
the cell mobility using the wound healing assay (Figure 5A).
The mobility of PC9/GR-shTAZ cells was dramatically de-
creased. Within 24 hours, the area of the wound was sig-
nificantly recovered by the migrating shNC group cells. In
marked contrast, the wound closure of TAZ-knocked-
down PC9/GR cells was only partial within 24 hours. The
motility and invasiveness of these cells were independently
assessed using the Transwell migration (Figure 5B) and
matrigel invasion assay (Figure 5C). Compared with con-
trol, the migration and invasiveness of TAZ-knocked-down
cells decreased 52% - 63% (PC9/GR-shTAZ1 versus PC9/
GR-shNC: P = 0.007, PC9/GR-shTAZ2 versus PC9/GR-shNC: P = 0.001) and 53% - 62% (PC9/GR-shTAZ1 versus
PC9/GR-shNC: P = 0.003, PC9/GR-shTAZ2 versus PC9/
GR-shNC: P < 0.001), respectively.
Discussion
Although tremendous progress has been made toward
understanding the molecular mechanism underlying
NSCLC development and treatment, the overall survival
of lung cancer patients is still significantly hindered be-
cause of the evolution of drug-resistant tumors. T790M
mutation-mediated gefitinib resistance accounts for 50%
of TKI resistance in patients carrying an EGFR mutation.
Accumulating evidence suggests that T790M-induced
resistance is not only caused by lowering the affinity for
gefitinib to nullify the hypersensitivity of activating
EGFR mutations [14], but also attributed to the gain of
Figure 5 Knockdown of TAZ in PC9/GR suppresses cell migration and invasion. (A) Wound-healing migration assay for PC9/GR cells
expressing shNC, shTAZ1 or shTAZ2. The healing of wounds by migrated cells at time 0 and 24 h was imaged. PC9/GR cells expressing shNC
migrated faster than PC9/GR cells knocking down TAZ. (B,C) The migration (B) and invasion (C) of control, PC9/GR cells expressing shNC, shTAZ1
or shTAZ2 were assessed by transwell assay and matrigel invasion assay. The migration and invasiveness of TAZ-knocked-down PC9/GR cells
decreased 52% - 63% and 53% - 62%, respectively, compared with control cells. Results are expressed as means ± SEM from three independent
experiments (** P<0.01, *** P<0.001). Statistical analyses were carried out using Student’s t-test.
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gressive advantage to cells expressing the T790M double
mutants, with increasing ligand-independent receptor
activation [3,4].
Recently, TAZ and its paralogue YAP have been identi-
fied as major proteins mediating the effects of the novel
Hippo tumor suppressor pathway. Several studies showed
that TAZ amplification existed in lung cancer, driving the
progression and metastasis of lung tumor-propagating
cells [15] and significantly correlated with the prognosis of
patients [11]. In this report, we have for the first time
identified TAZ as a novel gene responsible for sensitivity
of gefitinib in NSCLC harboring T790M mutation. By
overexpressing TAZ in gefitinib-sensitive PC9 cells, we
found that enhanced levels of TAZ directly reduced sensi-
tivity to growth inhibition induced by gefitinib, which
abolished by the inhibition of Akt signaling. On the other
hand, knockdown of endogenous TAZ in drug-resistantcells sensitized these cells to gefitinib. Therefore, targeting
TAZ in TAZ-overexpressed, T790M-induced resistance
might be a novel therapeutic strategy for sensitizing
EGFR-TKI treatment.
Consistent with our finding, some proteins in the
Hippo-LATS pathway have also been shown to mediate
the drug sensitivity in human cancers. For example, Yang
et al. have reported that TAZ and its downstream tran-
scriptional targets cysteine-rich 61 (Cyr61) and CTGF me-
diated Taxol resistance in breast cancer cells [16]. In a
screen of shRNAs, LATS1, a negative regulator of TAZ,
was identified as one of the genes causing paclitaxel resist-
ance upon knockdown in A549 cells [17]. Similarly, over-
expression of YAP, the TAZ paralogue, has been found to
involve in drug response of mammary [18], ovarian
[19,20], colon [21] and hepatocellular [22-25] cancers to
multiple chemotherapeutic and targeted therapies. In
addition, loss of other important tumor suppressor genes
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leads to drug resistance, whereas overexpression of CD44
or Itch, the negative regulators of the Hippo pathway, in-
duces drug resistance [26]. Together, these studies suggest
that the emerging Hippo pathway may have significant
roles in drug sensitivity of human cancers. Therefore, it
will be very interesting to examine how TAZ is responsible
for gefitinib sensitivity in NSCLC.
In current study, we provided evidence that endogenous
TAZ contributed to the tumorigenicity of NSCLC cells
harboring T790M mutant, as specific knockdown of TAZ
leaded to reduced anchorage-independent growth in vitro
and tumor formation in vivo. Preclinical and clinical data
suggest that markers of EMT may be associated with lim-
ited responses to EGFR-TKI, whereas retention of an epi-
thelial phenotype is associated with response even in
patients without EGFR receptor mutations [27]. Accumu-
lating evidence suggests TAZ promotes EMT-mediated
cancer progression [28,29]. Consistent with these conclu-
sion, our data showed knockdown of TAZ in PC9/GR was
correlated with EMT as the transfectants demonstrated
enhanced expression of epithelial marker (E-cadherin) but
reduced mesenchymal markers (vimentin, CTGF and
AXL). Furthermore, knockdown of TAZ in PC9/GR sup-
pressed cell migration and invasion, which were consid-
ered functional hallmarks of EMT. These observations
may partially explain the benefit of TAZ knockdown on
EGFR-targeted therapy.
We further found stable TAZ knockdown dramatically
reduced the expression of the classical Hippo target
CTGF, a gene that regulated EMT-like transition. We
showed that TAZ activated CTGF transcription by bind-
ing to and activating CTGF promoter. Consistent with
our findings, previous studies showed that CTGF caused
EMT-like cell fate mediated by TAZ-TEAD complex
[16,30,31] and CTGF expression could confer resistance
to chemotherapeutic agents through ERK1/2-dependent
Bcl-xL/cIAP1 up-regulation in mastocarcinoma [32] and
AMPK-dependent NF-κB pathway in osteosarcoma [33].
Tyrosine kinase AXL, a novel EMT marker and potential
therapeutic target for overcoming EGFR inhibitor resist-
ance [34], was also confirmed as a transcriptional target
of TAZ in current study. The synergistic interaction be-
tween EGFR and AXL signaling showed that AXL trans-
activation mediated by associated EGFR amplified the
response of a subset of downstream elements, quantita-
tively shifting emphasis of the downstream network
across multiple pathways [35]. Moreover, this transacti-
vation appeared to result from physical clustering inter-
actions, which are quantitatively restricted to certain
RTKs depending on a combination of intrinsic “affinity”
and expression [36]. Therefore, CTGF and AXL also
contribute to the potential explanations for TAZ-related
sensitivity of EGFR-TKI therapeutics.Conclusions
In conclusion, we have provided convincing evidence that
TAZ is a novel gene mediating tumorigenesis and EMT
correlated with gefitinib sensitivity of lung adenocarcin-
oma cells harboring EGFR T790M mutation. Further con-
firmation of our findings using clinical patient samples
will greatly facilitate our efforts in the sensitizing treat-
ment of EGFR-TKI-resistant lung cancers in the future.
Methods
Cell culture
Human bronchial epithelial cell line 16HBE and lung
adenocarcinoma cell line A549 were purchased from the
Cell Resource Center (Shanghai Institutes for Biological
Sciences, China). PC9, gefitinib-resistant PC9/GR, H1975
and cisplatin-resistant A549DDP cell lines were kindly
provided by Prof. Hongbing Shen (Nanjing Medical
University, Nanjing, China). All cells were grown in
DMEM medium containing 10% FBS, 2mM L-glutamine
and 100U/ml penicillin-streptomycin and incubated at
37°C with 5% CO2 in a humidified incubator. To maintain
drug resistance, PC9/GR and H1975 cells were grown in
DMEM containing 1 mg/ml gefitinib (Pure Chemistry Sci-
entific Inc.) and then in drug free DMEM two days before
experiments.
Plasmid and transfection
The target sequences that shTAZ1 and shTAZ2 aimed
to were GCGATGAATCAGCCTCTGAAT and AGG
TACTTCCTCAATCACA. PC9/GR and H1975 cells
reaching 80% confluence were transfected with pGPU6-
shTAZ in the presence of lipofectamine 2000 (Invitrogen).
PC9/GR-shNC, PC9/GR-shTAZ1 and PC9/GR-shTAZ2
cells were generated from G418 selection as described pre-
viously. The plasmid of pEX2-TAZ was purchased from
Origene (Rockville, MD, USA). pEX2-TAZ-S51A was
constructed using the QuickChange Mutagenesis Kit
(Stratagene) according to the manufacture's protocol. The
DNA of CTGF [nucleotide (nt) position −250 to −1] and
AXL (nt −1180 to −235) promoters were amplified by
PCR from genomic DNA extracted from 16HBE cells and
subsequently cloned into pGL3-basic luciferase reporter
vector (Promega).
Real-time PCR
Total RNA was extracted from cells with TRIzol reagent
(Invitrogen, San Diego, CA) according to the manu-
facturer’s instructions. cDNA was synthesized with the
PrimeScript RT reagent kit (TaKaRa, Dalian, China).
Quantitative RT-PCR was carried out with a SYBR Premix
Ex Taq kit (TaKaRa) on a 7500 real time PCR system
(ABI) as follows: 95°C for 30 s, 40 cycles at 95°C for 5 s,
and 60°C for 30 s. The primers used were as follows: TAZ
forward 5’-AGTACCCTGAGCCAGCAGAA-3’, reverse
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CCCTCGCGGCTTACCGACTGG-3’, reverse 5’-CACAG
GTCTTGGAACAGGCGC-3’; AXL forward 5’-TTTCCT
GAGTGAAGCGGTCT-3’, reverse 5’-CATCTGAGTGGG
CAGGTACA-3’; b-actin forward 5’-TGACGTGGACA
TCCGCAAAG-3’, reverse 5’-CTGGAAGGTGGACAGC
GAGG-3’.
Immunofluorescence and western blot
Cells were fixed with 4% paraformaldehyde, permeabilized
with 0.1% Triton X-100/PBS, blocked in 2% BSA/PBS and
probed with primary antibody against TAZ (1:200, Cell
Signaling Technology, Inc.), followed by incubation with
fluorescein isothiocyanate-conjugated secondary antibodies
(1:100, Sigma). Nuclei were stained with DAPI. All im-
munofluorescence was visualized by confocal microscopy
(LSM 700), and images were processed using Volocity soft-
ware (PerkinElmer Life Sciences). Images were quantitated
using Image J software. For western blot analysis, 20 μg
of whole-cell lysates and nuclear fractions were used.
Nitrocellulose membranes were incubated with antibodies
against TAZ, E-cadherin (1:200, Cell Signaling Technology,
Inc.), Vimentin (1:200, abcam), CTGF (1:200, Proteintech
Group, Inc.), AXL (1:200, abcam), tAKT, pAKT, tERK and
pERK (1:100, Cell Signaling Technology, Inc.), GAPDH
(1:5000, Santa Cruz Biotechnology) and histone H3
(1:2000, abcam) followed by horseradish peroxidase-linked
secondary antibody. The target protein was visualized by
chemiluminescence (Denville Scientific, Metuchen, NJ).
Cell viability assays
IC50 and inhibition rate of tumor growth was determined
by the MTT (3-[4,5-dimethylthia-zol-2-yl]-2,5-diphenyl-
tetrazolium bromide) assay (Sigma). Cancer cells were
seeded into 96-well plates, and treated with gefitinib at dif-
ferent concentrations. After incubation, the media was re-
placed with 50 μL of MTT reagent (2 mg/mL) followed by
further incubation in incubator for 2 h. Then, the media
were removed and dimethylsulfoxide (DMSO) (150 μL)
was added to each well. The absorbance at 560 nm was
measured with a spectrophotometer.
Colony formation assay
Stable PC9/GR cells knocking down TAZ or the empty
control were trypsinized and replated at 2 × 102 per well
in 6-well plates. After 14 days in culture in DMEM sup-
plemented with 10% FBS, colonies were fixed with 3.7%
methanol and stained with Giemsa. Colonies containing
at least 50 cells were scored.
Xenograft tumor model
Four- to 6-week-old female nude mice were inoculated
subcutaneously in the left and right thigh with 5 × 106
PC9/GR-shNC and PC9/GR-shTAZ2 cells suspended in100 μL of PBS to test tumorigenesis. Daily oral doses of
gefitinib (75 mg/kg) in captisol solution were adminis-
tered to tumor-bearing mice. Tumor size was measured
twice a week to follow the drug response in animal
model studies.Luciferase assay
Triplicates of 5 × 104 16HBE and PC9/GR cells in a 12-
well plate were transfected with CTGF-luc or AXL-luc
alone or together withTAZ or TAZ-S51A, using Lipofecta-
mine 2000 (Invitrogen). As an internal transfection con-
trol, 10 ng of Renilla luciferase vector was also
cotransfected in each sample. Luciferase activity was mea-
sured 2 days after transfection, using the Dual Luciferase
Reporter Assay System (Promega) and the Turner Biosys-
tems 20/20 Luminometer.Migration and invasion assays
Wound-healing assay was assessed by measuring the
movement of monolayer cells into a acellular area created
by a sterile plastic tip. The wound closure was photo-
graphed 24 h later by microscopy. Transwell migration
and matrigel invasion assays were conducted using trans-
well plates with 8 μm pore size membranes (Corning Inc.).
After incubation for 24 h, cells remaining in the upper side
of the filter were removed with cotton swabs. The cells at-
tached on the lower surface were fixed and stained. Cells
were counted with five high power fields per membrane
and results were presented as the mean number of cells
migrated per field per membrane.Statistical analysis
Statistical analysis was performed using the SPSS software
package (SPSS Standard version 16.0, SPSS Inc). Data
were shown as mean ± SEM. For in vitro and in vivo ex-
periments, independent-samples t-test was used for asses-
sing the significance of difference between the treatment
and control groups. P value <0.05 was considered as statis-
tically significant.Additional file
Additional file 1: Table S1. TaqMan-minor groove binder (MGB)
probes were used in a real-time PCR-based assay for the rapid and
accurate detection of PC9, PC9/GR and H1975 EGFR mutants. Loss of
mutant delE746-A750 EGFR gene was observed in PC9 cells. PC9/GR cells
harbored delE746-A750 plus T790M mutations. H1975 cells harbored
L858R and T790M mutations. The IC50 values of PC9, PC9/GR and H1975
cells to gefitinb were 0.16 ± 0.01 μmol/L, 1.27 ± 0.08 μmol/L and 5.35 ±
0.22 μmol/L by MTT, respectively. Data are shown as means± SEM. n= 3.
Statistical analyses were carried out using Student’s t-test.Competing interests
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